DNA microarray–based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy
- 31 July 2004
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 82 (1) , 132-137
- https://doi.org/10.1016/j.fertnstert.2003.12.034
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- CYP17 genetic polymorphism, breast cancer, and breast cancer risk factorsBreast Cancer Research, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Breast Cancer Risk Associated with CYP1A1 Genetic Polymorphisms in Japanese WomenThe Breast Journal, 2002
- Interaction of Hemostatic Genetics With Hormone TherapyChest, 2002
- Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal WomenJAMA, 2001
- Effects of Estrogen Replacement on the Progression of Coronary-Artery AtherosclerosisNew England Journal of Medicine, 2000
- Breast cancer risk associated with polymorphism inCYP19 in Japanese womenInternational Journal of Cancer, 2000
- Genetic variants of CYP19 (aromatase) and breast cancer riskOncogene, 2000
- Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancerPharmacogenetics, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998